Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 159 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: T2D medication management Clear all
Terminated Phase 4 Interventional Results available

Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

NCT03471117
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Pioglitazone, Placebo
Drug · Other
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
35 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Arlington, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 3, 2026, 2:37 AM EDT
Completed Not applicable Interventional

Targeting Hyaluronan Accumulation Through Exercise in T2DM

NCT04383314
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
10-week exercise program on HA accumulation
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Sep 3, 2026, 2:37 AM EDT
Completed Not applicable Interventional Results available

The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes

NCT02269098
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Medication Adherence, HYPERGLYCEMIA
Interventions
Diabetes medication management
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 3, 2026, 2:37 AM EDT
Completed Phase 3 Interventional Results available

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy

NCT01499095
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Lantus (Insulin glargine), HOE901-U300 (new formulation of insulin glargine)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
110
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Sep 3, 2026, 2:37 AM EDT
Terminated Not applicable Interventional

Primary Care-Based Physical Activity for Diabetic Latinas

NCT02741050
View directory record Official record
Conditions
Diabetes, Sedentary Lifestyle
Interventions
Tailored Physical Activity Intervention, Standard of Care
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 3, 2026, 2:37 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

NCT02738151
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
929 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
74
States / cities
Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Sep 3, 2026, 2:37 AM EDT
Completed Not applicable Interventional Results available

Assessing Home Food Environment and Diabetes Self-management Among Adult Type 2 Diabetes Patients

NCT03039569
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Text messaging
Behavioral
Lead sponsor
University of Nebraska Lincoln
Other
Eligibility
30 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Sep 3, 2026, 2:37 AM EDT
Recruiting Not applicable Interventional

Project Dulce for Arab Americans With Type 2 Diabetes

NCT05580536
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Project Dulce + Dulce Digital
Behavioral
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
El Cajon, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 3, 2026, 2:37 AM EDT
Completed Not applicable Interventional

One Drop Experts Program for Type 2 Diabetes Self-Management: Impact on A1c

NCT02827669
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
One Drop Experts Program, One Drop Experts Program + Apple Watch
Behavioral
Lead sponsor
Evidation Health
Industry
Eligibility
18 Years to 75 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 3, 2026, 2:37 AM EDT
Completed Not applicable Interventional

Rural Area Pharmacist Intervention for Diabetes

NCT05761886
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
telehealth-based clinical pharmacy intervention
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 3, 2026, 2:37 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

NCT02926937
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
56
States / cities
Tucson, Arizona • Anaheim, California • Canoga Park, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Sep 3, 2026, 2:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

FAMS Mobile Health Intervention for Diabetes Self-care Support

NCT02481596
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
REACH + FAMS, REACH, Helpline & A1c results
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 3, 2026, 2:37 AM EDT
Completed Not applicable Interventional Results available

Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes

NCT01073020
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Allergan Adjustable Gastric Band Surgery, Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group, Roux-en-Y Gastric Bypass (RYGB) Surgery, Intensive Medical Diabetes & Weight Management (Why WAIT) - Bypass Group
Device · Other · Procedure
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
21 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Sep 3, 2026, 2:37 AM EDT
Completed Not applicable Interventional Results available

Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19

NCT04591015
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Covid19
Interventions
Hospital: DD-CA, Hospital: Usual Care (UC)
Behavioral
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 3, 2026, 2:37 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04618744
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Interventions
ORMD-0801 (Insulin) capsule 8 mg BD, Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 3, 2026, 2:37 AM EDT
Completed Not applicable Interventional Results available

Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics

NCT03252964
View directory record Official record
Conditions
Type2 Diabetes
Interventions
Continuous Glucose Monitor (CGM), Activity Tracker, Coaching
Device · Behavioral
Lead sponsor
Savvysherpa, Inc.
Industry
Eligibility
65 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Sep 3, 2026, 2:37 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD

NCT04220021
View directory record Official record
Conditions
C9orf72 Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia
Interventions
Metformin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 3, 2026, 2:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinic to Community Connections - Broader Distribution

NCT04474795
View directory record Official record
Conditions
Gestational Diabetes, Gestational Diabetes Mellitus in Pregnancy
Interventions
Staff -Educational training
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Sep 3, 2026, 2:37 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

NCT02058160
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
108
States / cities
Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 3, 2026, 2:37 AM EDT
Completed Phase 4 Interventional Results available

Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus

NCT01226043
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 85 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2013 · Synced Sep 3, 2026, 2:37 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

NCT01798706
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
70 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
La Jolla, California • Norwalk, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 3, 2026, 2:37 AM EDT
Completed Phase 1 Interventional Results available

A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes

NCT01469065
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-04991532, PF-0499132, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Sep 3, 2026, 2:37 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Impact of Metabolic Health on Sperm Epigenetic Marks in Humans

NCT03860558
View directory record Official record
Conditions
Overweight, Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Interventions
Lifestyle Intervention, No Intervention
Other
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 3, 2026, 2:37 AM EDT
Completed Not applicable Interventional Results available

Improving Detection and Evidence-based Care of NAFLD in Latinx and Black Patients With Type 2 Diabetes

NCT05844137
View directory record Official record
Conditions
NAFLD, Diabetes Mellitus
Interventions
NAFLD Education, diet/lifestyle support, T2D medication management, clinically-indicated liver testing and care
Behavioral · Drug · Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 3, 2026, 2:37 AM EDT